kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human BCMA / TNFRSF17 Protein, Fc Tag, Avi Tag , premium grade DMF Filed, 25µg  

Recombinant Biotinylated Human BCMA / TNFRSF17 Protein, Fc Tag, Avi Tag , premium grade DMF Filed, 25µg

Recombinant Biotinylated Human BCMA / TNFRSF17 Protein, expressed from human 293 cells (HEK293), Met 1 - Ala 54, Fc Tag, Fc,Avitag™, premium grade

recombinant, human, biotinylated, protein, TNFRSF17,CD269,BCM,BCMA

More details


Availability: within 7 days

325,00 €

Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

Recombinant Biotinylated Human BCMA, Fc,Avitag, premium grade(BC7-H82F0) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 54 (Accession # NP_001183.2).
Predicted N-terminus: Met 1
It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. When ready to transition into later clinical phases, we also offer a custom GMP protein service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).
The protein has a calculated MW of 33.8 kDa. The protein migrates as 40-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Less than 0.01 EU per μg by the LAL method.

The sterility testing was performed by membrane filtration method.


>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 10 mM NaCl, pH7.5 with trehalose as protectant.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin"
Springer, Krauter, Trummer
Oncotarget (2023) 14, 949-956
(2) "[Development of Novel Gene-Modified T-Cell Therapies(CAR-T, TCR-T)]"
Gan To Kagaku Ryoho (2023) 50 (10), 1032-1037
(3) "Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma"
Xia, Zhao, Shen et al
Front Immunol (2023) 14, 1278749
Showing 1-3 of 1206 papers.